Novartis and Eli Lilly have opposed a petition before the Kerala High Court seeking government intervention to make two expensive breast cancer drugs more affordable, even as data placed before the court shows their combined sales in India account for a fraction of their global revenues, according to a report by ToI's Rema Nagarajan.
Novartis made about $12.7 billion from global sales of ribociclib between 2020 and 2025, while sales of the drug in India during the period stood at $55.7 million, or about 0.4% of its global revenue. Lilly's abemaciclib generated $19.6 billion globally during the same period, compared with $31.5 million in India, or about 0.16% of global sales.
